MedTrace Logo

Registry of Atrial Fibrillation and Embolic Risk in Mexico

NCT02334852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2017-04-11

No results posted yet for this study

Summary

The AF is the most common arrhythmia in clinical practice affecting 1-2% of the general population. It is the most common cause of cerebrovascular events (CVE), responsible for 25% of all ischemic strokes and 50% of cardioembolic strokes.

The CARMEN-AF registry is planned to be the first registry of non-valvular AF in Mexico with national representation, planning and specific objectives for publications. Follow-up period of two years is planned.

Conditions

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Medicaweb, S.A.C.V.

    collaborator INDUSTRY

  • Registro de Fibrilación Auricular y Riesgo Embólico en México

    lead OTHER

Principal Investigators

  • Manlio F Marquez-Murillo, MD · Instituto Nacional de Cardiología

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-12-31
Completion
2017-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02334852 on ClinicalTrials.gov